Immunotoxins Market Size & Share 2025 – 2034

Immunotoxins Market Size

The global immunotoxins market size was estimated at USD 159.9 million in 2024. The market is expected to grow from USD 171.9 million in 2025 to USD 345.5 million in 2034, at a CAGR of 8.1% during the forecast period.

Immunotoxin is a therapeutical agent that combines a targeted molecule or a monoclonal antibody with a toxin, which is a potent cytotoxic substance. The mechanism of action for this therapeutical agent involves the binding of the antibody to specific antigen present over the surface of the targeted cells such as the cancerous cell or other diseased cells, whereas the toxin part of the therapeutical agent works to kill the targeted cells by disrupting their cellular processes.
 

The growth of the market is highly attributed due to the growing prevalence of cancer and other chronic diseases worldwide. According to the data from the World Health Organization (WHO), in 2022, around 20 million people globally were diagnosed with cancer and 9.7 million deaths were reported. Moreover, as per the 2022 report of Global Cancer Observatory, lung cancer was the most common type of cancer worldwide with 2.5 million cases followed by breast cancer with 2.3 million cases, then colorectal cancer with 1.9 million cases, prostate cancer with 1.5 million cases, and stomach cancer with 970,000 cases.
 

Additionally, it is projected that by 2050, more than 35 million new cancer cases will be diagnosed which will be a 77% increase from the cases that were diagnosed in 2022. Therefore, as the prevalence of cancer increase so does the demand for advanced targeted treatment options such as immunotoxins. This therapeutical agent delivery a targeted therapy with its cytotoxic agent without causing any harm to the surrounding healthy cells, thereby fostering their demand in the cancer treatment and research, stimulating the market growth.
 

Furthermore, the rising adoption of the targeted therapies for treating chronic conditions is a key catalyst for the growth of the market. Targeted therapies including immunotoxin involves in treating specific cells or the antigen, which is responsible for the progression of the disease, reduces the rate of adverse reaction, ultimately enhancing the patients’ outcomes. Thus, due to these benefits offered by the targeted therapies such as the immunotoxins-based therapies, stimulating immunotoxins adoption in the research and treatment pertaining to cancer and chronic disease conditions, fostering the growth of the market.
 

Immunotoxins Market Trends

• Regulatory agencies across the world such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), among others are increasingly recognizing the role of immunotoxin in the treatment of cancer and other chronic disease conditions which in turn stimulated the approval for novel immunotoxins-based therapies and treatments for various types of cancer and chronic conditions.
   
• For instance, according to the 2022 study published by the Frontiers of Oncology, Ontak (Denileukindiftitox), Elzonris (Tagraxofusp-erzs), and Lumoxiti (Moxetumomabpasudotox-tdfk) are the bacterial derived immunotoxin based fusion treatment which have been approved by the U.S. Food and Drug Administration (FDA) with anti-cancerous properties.
   
• Therefore, as more immunotoxins-based therapies gain regulatory backing, their accessibility continues to improve, facilitating wider adoption and will stimulate the further demand of immunotoxin for cancer therapy in the market, ultimately accelerating the market growth.
   
• Moreover, the rising research and development investments by the government organization to the research and academic institutes are accelerating the innovations in immunotoxins efficiency, enhancing the targeted delivery mechanism, and significantly reducing the immunogenicity.
   
• Thus, such investment plays a crucial role in addressing the expanding demand of the innovative oncology, which is estimated to reach USD 866.1 billion by 2034, therapies and immunotherapeutic interventions, thereby propelling the market growth.
   

Immunotoxins Market Analysis

Based on toxin type, the market is divided into diphtheria toxins (DT), anthrax-based toxins, pseudomonas exotoxins (PE), ribosomes inactivating protein based immunotoxins, and other immunotoxins. The global market was estimated at USD 159.9 million in 2024. The diphtheria toxins (DT) segment held revenues of USD 61.9 million in the year 2024 and the segment is poised for significant growth at a CAGR of 8.1% during the forecast period.
 

• The growth of the segment is highly attributed due to the well-established application and proven efficacy of the diphtheria toxins (DT) to treat variety of the cancers. Diphtheria toxins (DT) possess strong mechanism of action, it works by inhibiting protein synthesis in the targeted cell, leading to cell death.
   
• For instance, Ontak (denileukin diftitox) is an FDA approved therapeutical agent based on the diphtheria toxins (DT) that is intended for the use in the patient suffering from the persistent or recurrent cutaneous T-cell lymphoma.
   
• Denileukin diftitox is a fusion protein that directs the cytocidal action of diphtheria toxin towards the cells expressing the IL-2 receptor. Ex vivo studies indicate that upon binding to the IL-2 receptor on the cell surface, the drug undergoes receptor-mediated endocytosis. Once internalized, the fusion protein is cleaved, releasing enzymatic and translocation domains of diphtheria toxin from the IL-2 fragment, resulting in the inhibition of protein synthesis and ultimately cell death.
   
• Thus, the rising adoption of the diphtheria toxins (DT) based immunotoxin in the field of oncology, stimulated by their strong therapeutical potential and targeted mechanism of action is fueling the market growth.
   
• Moreover, the FDA approval of the Ontak and ongoing research on diphtheria toxins (DT) based immunotoxin, further fostering the growth of the segment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the immunotoxins market is bifurcated into biomedical research and therapy development. The therapy development segment dominated the global market accounting for 59.8% market share in 2024.
 

• The growth of the segment is highly owing to the factor such as increasing prevalence of cancer and the rising adoption of the immunotoxin in the clinical environment.
   
• Rising prevalence of cancer especially hematological malignancies, such as   leukemia, lymphoma, and multiple myeloma are the major catalyst that is accelerating the of demand for the development of immunotoxin-based therapies.
   
• For instance, as per the data from the Leukemia & Lymphoma Society (LLS), in 2024 it was estimated that 187,740 individuals in the U.S. will be diagnosed with leukemia, lymphoma, and myeloma.
   
• Therefore, as the rate of diagnosis of these cancers increase so does the need for the development of new targeted therapies such as immunotoxin-based therapies.
   
• For example, ELZONRIS (tagraxofusp-erzs) which is a fusion protein comprised of a recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT), intended for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) a form of rare hematological malignancies.
   
• Therefore, as the clinical efficacy of immunotoxins increases, so does the adoption of these toxin in the development of new therapies pertaining to various types of chronic diseases, propelling the segmental growth.
   

Based on end use, the immunotoxins market is bifurcated into pharmaceutical and biotechnology companies, CROs and CMOs, academic and research institutes, and other end users. The pharmaceutical and biotechnology companies segment dominated the global market accounting for USD 75.5 million in 2024.
 

• These companies invest heavily in the research and development activities in order to develop advanced targeted cancer and other chronic disease treatments through immunotoxin, which effectively target the diseased cell while minimizing the damage to the healthy surrounding cells.
   
• Additionally, the pharmaceutical and biotechnology companies play a significant role in the process of drug development and discovery, clinical trials, regulatory approval, among others.  
   
• Moreover, the partnership with the contract research organizations (CROs), academic institutions, and contract manufacturing organizations (CMOs), help these companies to accelerate the product commercialization and product development, further fostering the segmental growth.
   

The U.S. immunotoxins market is projected to grow significantly, reaching USD 124.9 million by 2034.
 

• The rising prevalence of the cancer and related deaths is one of the key catalysts for the growth of the market in the country.
   
• For instance, as per the data from the American Cancer Society, approximately 2,001,140 new cancer cases were estimated to be diagnosed in the country, alongside with 611,720 cancer related deaths in 2024.
   
• Therefore, as the rate cancer and cancer related deaths increases in the country, so does the need for therapy based on immunotoxin, which provides a targeted and effective treatment option to treatment different form of cancer, fostering the growth of the market in the country.
   

Europe: The immunotoxins market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The UK is the hub for cutting edge oncology treatment and diagnosis, supported by various organizations such as Cancer Research UK and National Institute for Health and Care Research (NIHR). These organizations significantly invest in the research and development of novel therapies to combat the chronic conditions such as cancer.
   
• For instance, in 2022, as per the data from University of Oxford, the Cancer Research UK had invested around EUR 11 million in the cancer science research in Oxford.
   
• Thus, such investment is anticipated to accelerate the growth of the market in the country.
   

Asia Pacific: Japan immunotoxins market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The country as one of fastest-aging populations. This demographic is highly susceptible to age related chronic diseases such cancer and other chronic conditions thereby increasing the need for targeted cancer therapies among them.
   
• For example, in 2023 projections from the World Economic Forum revealed that 1 in 10 people in Japan are aged 80 years and above which is about one-third of the population.
   
• Thus, as the population ages in the country so does the chances of cancer and need for targeted cancer therapies such as immunotoxin-based therapies, thereby fostering the immunotoxin market growth in the country.
   

Middle East and Africa: The immunotoxins market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The Saudi government is actively investing in healthcare infrastructure and biotechnology as part of Vision 2030, which aims to enhance medical research, local pharmaceutical production, and innovative treatment availability.
   
• Increased funding for cancer research and immunotherapy development is expected to boost the adoption of immunotoxin-based therapies in the country, fostering the market growth in the country.
   

Immunotoxins Market Share

The top 4 players of the market account for approximately 30% of the market share which includes companies such as Creative Biolabs, Merck KGaA, List Biological Laboratories, and The Native Antigen Company. Companies are concentrating on enhancing the efficacy and safety of immunotoxin, while also meeting the growing demand for targeted treatments that minimize side effects. Strategic partnerships with oncology clinics, research organizations, and pharmaceutical companies are crucial for expanding market reach and ensuring the seamless integration of immunotoxins into cancer care protocols. These strategies are vital for companies to maintain a competitive advantage and support sustained growth in the evolving immunotoxin market.
 

Immunotoxins Market Companies

Some of the eminent market participants operating in the immunotoxins industry include:

• Abcam
• Bio-Techne
• Cayman Chemical
• Creative Biolabs
• Enzo Biochem
• List Biological Labs
• Merck KGaA
• Quadratech Diagnostics
• Santa Cruz Biotechnology
• The Native Antigen Company
• Thermo Fisher Scientific
   
• Thermo Fisher Scientific has a strong focus on R&D activities, the company has invested approximately USD 1,390 million in financial year 2024.
   
• Merck KGaA has a strong financial position; the company had reported a total revenue of USD 22,028 million for the financial year 2023.
   

Immunotoxins Industry News:

• In December 2022, Merck announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc. to discover novel antibody-drug conjugates (ADCs) utilizing Mersana’s proprietary Immunosynthen STING-agonist ADC platform, targeting up to two cancer-related antigens. This partnership enabled Merck to develop more effective, targeted therapies with the potential for fewer side effects, providing a promising solution for difficult-to-treat cancers.
   

The immunotoxins market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Toxin Type

• Diphtheria toxins (DT)
• Anthrax based toxins
• Pseudomonas exotoxins (PE)
• Ribosomes inactivating protein based immunotoxins
• Other toxin types    

Market, By Application

• Biomedical research
• Therapy development

Market, By End Use

• Pharmaceutical and biotechnology companies
• CROs and CMOs
• Academic and research institutes
• Other End Use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE